A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever

Cell Rep. 2022 Jul 19;40(3):111094. doi: 10.1016/j.celrep.2022.111094.


Lassa virus (LASV) is recognized by the World Health Organization as one of the top five pathogens likely to cause a severe outbreak. A recent unprecedented resurgence of LASV in Nigeria caused by genetically diverse strains underscores the need for licensed medical countermeasures. Single-injection vaccines that can rapidly control outbreaks and confer long-term immunity are needed. Vaccination of cynomolgus monkeys with a recombinant vesicular stomatitis virus vector expressing the glycoprotein precursor of LASV lineage IV strain Josiah (rVSVΔG-LASV-GPC) induces fast-acting protection in monkeys challenged 3 or 7 days later with a genetically heterologous lineage II isolate of LASV from Nigeria, while nonspecifically vaccinated control animals succumb to challenge. The rVSVΔG-LASV-GPC vaccine induces rapid activation of adaptive immunity and the transcription of natural killer (NK) cell-affiliated mRNAs. This study demonstrates that rVSVΔG-LASV-GPC may provide rapid protection in humans against LASV infections in cases where immediate public-health intervention is required.

Keywords: CP: Immunology; Lassa virus; T cell; arenavirus; hemorrhagic fever; immunity; natural killer cell; primate; vaccine; vesicular stomatitis virus.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Humans
  • Lassa Fever* / prevention & control
  • Lassa virus
  • Macaca fascicularis
  • Vaccines, Synthetic
  • Viral Vaccines*


  • Vaccines, Synthetic
  • Viral Vaccines